Board of Directors

EffRx’s Board of Directors has extensive experience in successfully starting and managing companies, including specialty pharmaceutical companies in the U.S. and abroad. The Board plays an active role in the strategic decision-making in the company. EffRx fully leverages the vast experience and relationships of the Board in building a global specialty pharmaceutical business through successful partnerships.


Dr. Jonas Ekblom

Chairman

Dr. Jonas Ekblom has over 25 years of experience from the life science sector, with a focus in pharmacology and drug development.

He has managed R&D programs in multiple fields of medical technology in several therapeutic areas. Dr. Ekblom has held senior management positions in Pharmacia, Biovitrum, Sequenom and Invitrogen (now Thermo Fisher). Since 2008, Dr. Ekblom has worked as a C-level executive in several biotechs, including serving as CEO of Bows Pharmaceuticals AG, a Swiss drug delivery company and later CEO of the Promore Pharma group, a public biopharmaceutical innovation company in Sweden.

He has published over 60 peer-reviewed articles and holds a position as Associate Professor in Pharmacology at Uppsala University, Sweden.

Dr. Ekblom also serves on the Board of Directors of several life sciences companies, including Pergamum AB and World 5 Ventures.

Dr. Alcide Barberis

Board Member

Dr. Alcide Barberis is a biotech entrepreneur and manager with over 20 years of management experience in the biotechnology industry and scientific experience in the private and public research sectors. He is currently CEO of Mabylon AG and was previously CEO of Humabs BioMed, now a subsidiary of VIR Biotechnology.

His career includes entrepreneurial start-ups (co-founder of ESBATech AG and Oncalis AG), executive management, R&D management and business development. Dr. Barberis has been a member of the Board of Directors of ESBATech and Oncalis and is currently a member of the Board of Directors of Mabylon. In his roles as biotech manager, he successfully negotiated collaboration and licensing deals with pharma companies and contributed to fundraising campaigns with private investors and VCs.

Dr. Barberis holds a Ph.D. in Molecular Biology and Biochemistry from the University of Zürich.